文献速递乳腺癌放疗放疗物理与技术

老年早期乳腺癌单次术中加速部分乳腺照射的五年肿瘤学结局

Five-year oncological outcome after a single fraction of accelerated partial breast irradiation in the elderly.
PubMed 文献 · Radiat Oncol · 2019-12-21

单中心回顾性队列更新65岁以上低危乳腺癌患者接受术后单次16 Gy多导管组织间高剂量率近距离放疗(MIB)加速部分乳腺照射(APBI)的5年结局。48例女性51个病灶,中位随访64个月,无局部复发,1例腋窝复发,无≥3级晚期毒性,优良美容结局率76.4%。

要点

  • 术后单次16 Gy MIB APBI在老年低危乳腺癌中5年无局部复发。
  • 中位随访64个月仅1例腋窝复发(2.1%),无≥3级晚期毒性。
  • 优良美容结局率76.4%,支持该方案作为术中放疗的替代选择。

核心结论

  • 术后单次16 Gy MIB APBI在老年低危乳腺癌患者中安全且临床结局令人鼓舞。

研究设计与样本

  • 单中心回顾性队列研究,纳入≥65岁低危乳腺癌患者,行肿物切除加腋窝评估后接受MIB APBI。
  • 2012年1月至2015年8月共治疗48例女性(51个病灶),中位年龄77.7岁(范围65-92)。

主要发现

  • 中位随访64个月(范围56-71),无局部复发,1例(2.1%)发生腋窝复发。
  • 未观察到≥3级晚期毒性,共16次晚期毒性事件,其中G1 14次(87.5%),主要为G1乳腺纤维化。
  • 优良美容结局率为76.4%。

关键数值与推荐

  • 处方剂量为单次16 Gy,参考100%等剂量线。
  • 中位肿瘤大小12 mm(范围3-32),5例腋窝淋巴结受累(4例Nmic,1例N1)。
  • 浸润性导管癌为最常见组织学类型(86.3%)。

临床怎么用

  • 对于术后病理报告符合APBI条件的老年低危乳腺癌患者,可考虑单次MIB APBI作为术中放疗的替代方案。

局限性

  • 单中心回顾性设计,样本量较小(48例),随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To update the clinical outcome of an elderly women cohort with early breast cancer who underwent accelerated partial breast irradiation (APBI) based on a post-operative single fraction of multicatheter interstitial high dose-rate brachytherapy (MIB). MATERIAL AND METHODS: A single institution retrospective cohort study was performed focusing on elderly patients (≥ 65 years old) presenting a low-risk breast carcinoma treated by lumpectomy plus axillary evaluation followed by MIB APBI. A single fraction of 16 Gy was prescribed on the 100% isodose. Clinical outcome at 5 years was reported based on local relapse free survival (LRFS), specific survival (SS) and overall survival (OS). Late toxicity was evaluated. Cosmetic results were evaluated clinically by the physician. RESULTS: Between January 2012 and August 2015, 48 women (51 lesions) were treated. Median age was 77.7 years (range: 65-92) with a median tumor size of 12 mm (range: 3-32). Five patients (pts) presented an axillary lymph node involvement (4 Nmic, 1 N1). Invasive ductal carcinoma was the most frequent histology type (86.3%). With a median follow-up of 64 months (range: 56-71), no local relapse occurred while 1 pt. developed an axillary relapse (2.1%). No Grade 3 or higher late toxicity was observed while 16 late toxicities occurred (G1: 14 events [87.5%) mainly G1 breast fibrosis). The rate of excellent cosmetic outcome was 76.4%. CONCLUSION: We confirmed the safety of the process and remained encouraging clinical outcome of a post-operative single fraction of MIB ABPI in the elderly. This approach leads to consider a very APBI as an attractive alternative to intra-operative radiation therapy while all the patients will be good candidates for APBI in regards to the post-operative pathological report.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kinj R, Chand ME, Gal J, et al. Five-year oncological outcome after a single fraction of accelerated partial breast irradiation in the elderly. Radiat Oncol. 2019. PMID: 31864391. doi:10.1186/s13014-019-1448-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。